Abstract
Background: The outcome of neonatal septic neutropenia is poor.
Methods Uncontrolled pilot study of rhG-CSF as adjuvant therapy in 12 neutropenic preterm infants (24-35 weeks gestation). All received appropriate antibiotics.
Six infants recovered from acute, severe illness (4 with confirmed and 2 with probable sepsis). Four infants died from respiratory distress syndrome; 2 others were moribund pre-treatment and died after their first doses of rhG-CSF.
Conclusions RhG-CSF may correct neutropenia; prophylactic use is likely to be of more benefit than interventional use; thrombocytopenia may be a side effect.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bedford Russell, A., Davies, E., Ball, S. et al. 19 Treatment of neonatal neutropenia with recombinant humar granulocyte colony-stimulating factor (rhG-CSF. Pediatr Res 36, 6 (1994). https://doi.org/10.1203/00006450-199407000-00019
Issue Date:
DOI: https://doi.org/10.1203/00006450-199407000-00019